Form 4: KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici

KalVista Pharmaceuticals has been acquired by Chiesi Farmaceutici in an all-cash transaction valued at $27.00 per share.

Summary

• KalVista Pharmaceuticals, Inc. completed its merger with a subsidiary of Chiesi Farmaceutici S.p.A. on June 11, 2026.
• The transaction involved a cash tender offer for all outstanding common stock at a price of $27.00 per share.
• As a result of the merger, KalVista is now a wholly owned subsidiary of Chiesi Farmaceutici.
• All outstanding stock options and restricted stock units (RSUs) held by the Chief Medical Officer were cancelled and converted into cash payments based on the $27.00 merger consideration.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the merger provides a definitive liquidity event at a fixed cash price.

Positives

• Shareholders received a definitive cash exit at $27.00 per share.
• Outstanding equity awards were fully vested and converted into cash, providing immediate liquidity to the reporting person.

Negatives

• The company has ceased to be an independent publicly traded entity.

Risks

• No ongoing risks as the company is now a private subsidiary.

Future Outlook

The company is now a wholly owned subsidiary of Chiesi Farmaceutici S.p.A. and no longer provides independent public guidance.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated April 29, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large global pharmaceutical companies acquiring specialized biotech firms to bolster their pipelines in rare disease and specialty therapeutic areas.

Comparison to Industry Standards

• The $27.00 per share cash consideration represents a standard exit strategy for clinical-stage biotech companies being absorbed by larger multinational pharmaceutical entities.

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders have been cashed out at the agreed merger price.
• The company is now integrated into Chiesi Farmaceutici's corporate structure.

Next Steps

• Delisting of KalVista Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

KalVista Pharmaceuticals, Chiesi Farmaceutici, Merger, Acquisition, KALV, Tender Offer